NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2468-2476

  Suzuki, Naoki ^a,b   Motohashi, Norio ^a   Uezumi, Akiyoshi ^a   Fukada, So Ichiro ^a   Yoshimura, Tetsuhiko ^c   Itoyama, Yasuto ^b   Aoki, Masashi ^b   Miyagoe Suzuki, Yuko ^a   Takeda, Shin'ichi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Yamagata Promotional Organization for Industrial Technology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 NITROINDAZOLE; NITRIC OXIDE SYNTHASE; PROTEIN MAFBX; PROTEIN MORF1; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; ELECTRON SPIN RESONANCE; FEMALE; MOUSE; MUSCLE ATROPHY; MUSCLE DENERVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SARCOLEMMA; UPREGULATION;

ANIMALS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; I-KAPPA B KINASE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCULAR ATROPHY; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITROSATION; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; SARCOLEMMA; SIGNAL TRANSDUCTION; SUSPENSIONS; TAIL;

EID: 34848913758     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30654     Document Type: Article

References (42)

1. Tidball, J.G. 2005. Mechanical signal transduction in skeletal muscle growth and adaptation. J. Appl. Physiol. 98:1900-1908.
2. Ikemoto, M., et al. 2001. Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway. FASEB J. 15:1279-1281.
3. Bodine, S.C., et al. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:1704-1708.
4. Gomes, M.D., Lecker, S.H., Jagoe, R.T., Navon, A., and Goldberg, A.L. 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U. S. A. 98:14440-14445.
5. Bodine, S.C., et al. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3:1014-1019.
6. Song, Y.H., et al. 2005. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest. 115:451-458. doi:10.1172/JCI200522324.
7. Rommel, C., et al. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:1009-1013.
8. Latres, E., et al. 2005. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 280:2737-2744.
9. Cai, D., et al. 2004. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119:285-298.
10. Sandri, M., et al. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399-412.
11. Li, Y.P., Schwartz, R.J., Waddell, I.D., Holloway, B.R., and Reid, M.B. 1998. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 12:871-880.
12. Greer, E.L., and Brunet, A. 2005. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 24:7410-7425.
13. Lehtinen, M.K., et al. 2006. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell. 125:987-1001.
14. Matsumoto, M., Han, S., Kitamura, T., and Accili, D. 2006. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest. 116:2464-2472. doi:10.1172/JCI27047.
15. Berman, J., and Kenyon, C. 2006. Germ-cell loss extends C. elegans life span through regulation of DAF-16 by kri-1 and lipophilic-hormone signaling. Cell. 124:1055-1068.
16. Lecker, S.H., et al. 2004. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18:39-51.
17. Kamei, Y., et al. 2004. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J. Biol. Chem. 279:41114-41123.
18. Skurk, C., et al. 2005. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 280:20814-20823.
19. Obsilova, V., et al. 2005. 14-3-3 Protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4. Biochemistry. 44:11608-11617.
20. Hunter, R.B., et al. 2002. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J. 16:529-538.
21. Hunter, R.B., and Kandarian, S.C. 2004. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J. Clin. Invest. 114:1504-1511. doi:10.1172/JCI200421696.
22. Acharyya, S., et al. 2005. Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 8:421-432.
23. Acharyya, S., et al. 2004. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114:370-378. doi:10.1172/JCI200420174.
24. Brenman, J.E., Chao, D.S., Xia, H., Aldape, K., and Bredt, D.S. 1995. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 82:743-752.
25. Kameya, S., et al. 1999. Alpha1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J. Biol. Chem. 274:2193-2200.
26. Hosaka, Y., et al. 2002. Alpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration. J. Cell Biol. 158:1097-1107.
27. Lecour, S., et al. 2001. Levels of nitric oxide in the heart after experimental myocardial ischemia. J. Cardiovasc. Pharmacol. 37:55-63.
28. Asanuma, K., et al. 2005. Diffusion of cytotoxic concentrations of nitric oxide generated luminally at the gastro-oesophageal junction of rats. Gut. 54:1072-1077.
29. Nagano, T., and Yoshimura, T. 2002. Bioimaging of Nitric Oxide. Chem. Rev. 102:1235-1270.
30. Kato, N., Sato, S., Yokoyama, H., Kayama, T., and Yoshimura, T. 2005. Sequential changes of nitric oxide levels in the temporal lobes of kainic acid-treated mice following application of nitric oxide synthase inhibitors and phenobarbital. Epilepsy Res. 65:81-91.
31. Moore, P.K., and Bland-Ward, P.A. 1996. 7-nitroindazole: an inhibitor of nitric oxide synthase. Methods Enzymol. 268:393-398.
32. Reynaert, N.L., et al. 2004. Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc. Natl. Acad. Sci. U. S. A. 101:8945-8950.
33. Hu, M.C., et al. 2004. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 117:225-237.
34. Segalat, L., Grisoni, K., Archer, J., Vargas, C., Bertrand, A., and Anderson, J.E. 2005. CAPON expression in skeletal muscle is regulated by position, repair, NOS activity, and dystrophy. Exp. Cell Res. 302:170-179.
35. Shiao, T., et al. 2004. Defects in neuromuscular junction structure in dystrophic muscle are corrected by expression of a NOS transgene in dystrophin-deficient muscles, but not in muscles lacking alpha- and beta1-syntrophins. Hum. Mol. Genet. 13:1873-1884.
36. Kapur, S., Bedard, S., Marcotte, B., Cote, C.H., and Marette, A. 1997. Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes. 46:1691-1700.
37. Stamler, J.S., and Meissner, G. 2001. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 81:209-237.
38. Yoshida, M., et al. 1995. Dystrophin-associated protein A0 is a homologue of the Torpedo 87K protein. FEBS Lett. 367:311-314.
39. Yusuf, I., Zhu, X., Kharas, M.G., Chen, J., and Fruman, D.A. 2004. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood. 104:784-787.
40. Huang, H., Regan, K.M., Lou, Z., Chen, J., and Tindall, D.J. 2006. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 314:294-297.
41. Kandarian, S.C., and Jackman, R.W. 2006. Intracellular signaling during skeletal muscle atrophy. Muscle Nerve. 33:155-165.
42. Mochizuki, Y., et al. 2005. Participation of bone marrow-derived cells in fibrotic changes in denervated skeletal muscle. Am. J. Pathol. 166:1721-1732.